New immune cell therapy targets stubborn cancers
NCT ID NCT04427449
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This early-phase trial is testing a new type of cell therapy called 4SCAR-CD44v6 T cells for people with cancers that have a specific marker called CD44v6. The treatment involves taking a patient's own immune cells, engineering them to better recognize and attack cancer cells, and infusing them back. The study will enroll 100 participants to check safety and whether the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCERS WHICH ARE CD44V6 POSITIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenzhen Hospital of Southern Medical University
RECRUITINGShenzhen, Guangdong, 518101, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Seventh Affilliated Hospital, Sun Yat-Sen University
RECRUITINGShenzhen, Guangdong, 518107, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
4SCAR-CD44v6 T cells (engineered immune cells)
What this could lead to
If it works, this could point toward a new treatment option for certain hard-to-treat cancers that carry the CD44v6 marker.
What could go wrong
This is an early phase 1/2 trial with only 100 participants, so results are preliminary. The therapy may cause serious side effects, and it is not yet known if it will shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.